TNF and type 1 diabetes mellitus: Despite existing challenges, registrational clinical trials using adaptive designs or combination approaches that couple TNF-α inhibitors with an agent with a different mechanism of action represent an opportunity to advance TNF-α inhibitors for treating people with stage 3 T1D.